Mitochondrial Therapy: New ‘Capsule’ Delivery System Shows Promise for Parkinson’s & Aging
Scientists in China have achieved a significant breakthrough in regenerative medicine with the development of a novel “capsule” delivery system for transplanting healthy mitochondria into diseased cells. The research, published in the journal Cell, offers a potential therapeutic avenue for conditions like Parkinson’s disease, rare genetic disorders, and age-related decline.
Mitochondria, often referred to as the “powerhouses” of the cell, are responsible for converting nutrients into energy. Defects in mitochondrial DNA can disrupt this process, leading to a range of debilitating diseases affecting approximately one in 5,000 people worldwide. Currently, treatment options primarily focus on managing symptoms rather than addressing the underlying mitochondrial dysfunction, according to Liu Xingguo, lead researcher at the Chinese Academy of Sciences’ Guangzhou Institutes of Biomedicine and Health.
A major obstacle in mitochondrial therapy has been the fragility of these organelles. Traditional attempts to inject mitochondria into tissues often result in their destruction. To overcome this, Liu’s team, collaborating with Guangzhou Medical University and other institutions, engineered a protective delivery vehicle using membranes derived from red blood cells. These membranes form capsules approximately 1 micrometer in diameter – one-thousandth of a millimeter – encapsulating the healthy mitochondria. This shell shields the mitochondria from the body’s natural defenses, allowing them to fuse with the recipient cell and restore energy production.
The team tested the technique on mice models of various mitochondrial diseases. In studies focused on Parkinson’s disease, the encapsulated mitochondria prevented neuronal death, restored normal energy function, and significantly improved motor skills. These findings align with ongoing research into cell-based therapies for Parkinson’s, including trials involving the transplantation of dopaminergic neurons, as detailed in a 2023 systematic review published in PubMed. That review noted beneficial effects of homogenous cell therapy on motor function even after 36 months of follow-up.
the treatment demonstrated efficacy in models of mitochondrial DNA depletion syndrome, a severe condition characterized by insufficient mitochondrial DNA. The encapsulated mitochondria significantly extended the lifespan of the mice and prevented organ failure. This suggests the potential for “recharging” aging organs and reversing age-related decline. A recent phase I/II trial at Kyoto University Hospital, published in Nature in April 2025, showed promising results with iPS-cell-derived dopaminergic cells, demonstrating survival and dopamine production without tumor formation, further bolstering the field of organelle therapy.
Researchers describe this advancement as a milestone in organelle therapy, a burgeoning field that utilizes the cell’s own machinery for therapeutic purposes, bypassing the need for traditional drugs or gene editing. “Healthy organelles such as mitochondria may potentially be used as a form of medicine to be directly delivered into patients to restore the functions of diseased tissues and organs,” Liu stated.
While the results in mice are encouraging, further clinical trials are necessary to assess the safety and efficacy of this “capsule” method in human patients. The next steps involve rigorous testing to ensure the treatment’s long-term safety and effectiveness before it can be considered for widespread clinical application.